跳至主要内容
临床试验/NCT02264899
NCT02264899已完成不适用

MEMENTO-VAScular COmponents of Dementia

University Hospital, Bordeaux11 个研究点 分布在 1 个国家目标入组 332 人开始时间: 2014年11月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
332
试验地点
11
主要终点
Change in cognitive performances over

研究概览

简要总结

A Multicenter national longitudinal cohort study including at least 800 individuals recruited from French Research Memory Centers and followed up over 36 months and included in Memento.

详细描述

Alzheimer's disease (AD) is a neurodegenerative disorder thought to be caused by the accumulation of the peptide amyloid beta and the hyperphosphorylated tau protein in the brain. There are increasing arguments in favor of an important role of vascular damages in the development and progression of AD.

The time course of these vascular alterations and how they relate to dementia and AD pathology remain unclear, as no protocol that allows the development of the diverse vascular pathology to be scored, and hence to be tracked with ageing, has so far been developed and widely validated. The aims of this project are to investigate, in a large clinical sample of patients presenting either isolated cognitive complaints or light to mild cognitive deficits, how vascular risk factors and vascular alterations (assessed at macro and micro levels) relate to cerebrovascular disease and cognitive decline.

The primary objective of this ancillary study is to investigate the prospective association between vascular risk factors, inflammation markers and vascular damages on cognitive decline and neurodegeneration progression over up to 4 years of follow-up in a sample of individuals presenting with a spectrum of cognitive profiles ranging from isolated cognitive complaints to cognitive deficits without dementia.

The secondary objectives are the following

  • To investigate the role of vascular risk factors (diabetes, hypertension, hypercholesterolemia) and vascular damages on progression to clinical dementia over up to 4-year follow-up.
  • To study whether the interaction between changes in markers of macrovascular and microvascular structures on cognitive deficits progression.
  • To study the association between in BP, hypertension, antihypertensive treatments and vascular damages, progression of cerebrovascular disease seen at MRI and cognitive decline and dementia risk
  • To assess the temporality of vascular damages burden on neurodegeneration
  • To assess the association between retinal vasculature defect and brain neurovascular damages
  • To study the link between vascular damages and AD pathology (Cerebro-Spinal Fluid (CSF) and Positron emission tomography (TEP) amyloid imaging) biomarkers in the subsample of participants having all measures available
  • To investigate how inflammatory markers mediate the association between vascular damages and neurodegeneration
  • To assess whether vascular factors and neurodegenerative factors act independently or synergistically on the course of cognitive decline
  • To assess simultaneously the impact of vascular damages on end organs (brain, eye, and kidney)
  • To study the correlation between cerebral blood flow, measured by Arterial spin-Labeled (ASL) MRI and cognitive decline
  • To study whether genetic polymorphisms revealed from genome-wide association studies (GWAS) of AD of vascular factors could modulate the association between vascular damages and cognitive decline

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants to MEMENTO-Vascod should be included in MEMENTO.
  • To have signed a specific MEMENTO-Vascod informed consent form, prior to any Vascod ancillary study related procedures
  • To be aged 50 years old and above
  • To have a Clinical Dementia Rating scale <0.5 and to be not demented;

排除标准

  • Are under guardianship
  • Live in skilled nursing facility
  • Are Pregnant or breast feeding women
  • Meet brain MRI exclusion criteria (Same criteria as in Memento main protocol)

结局指标

主要结局

Change in cognitive performances over

时间窗: 36 months from baseline

次要结局

  • Progression to clinical dementia of Alzheimer's type according to standardized criteria(36 months from baseline)
  • Change in CSF and blood amyloid biomarkers of AD(24 months from baseline)
  • Change in brain atrophy and hippocampal volumes(24 months from baseline)
  • Progression of small vessels disease markers (white matter lesions, lacunar infarcts, microbleeds)(24 months from baseline)

研究者

发起方
University Hospital, Bordeaux
申办方类型
Other
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验